V

Velocity Clinical Research | Dallas, TX

Research site

(Unclaimed)

Location

7777 Forrest Lane, Suite C685, Dallas, Texas, United States of America

Site insights

Top conditions

Top treatments

RO7795081

RGT001-075

BMF-219

CRB-913

ION224

Parent organization

This site is a part of Velocity Clinical Research

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 9 total trials

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity (CANYON-1)

This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body.The study has two parts: Part 1 will measur...

Enrolling

Obese But Otherwise Healthy Participants

Drug: CRB-913

Drug: Placebo

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tol...

Active, not recruiting

Obesity or Overweight

Drug: RO7795081

Drug: Placebo

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study...

Enrolling

Type 2 Diabetes Mellitus

Drug: Semaglutide

Drug: Placebo

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions (COMO-1)

This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss...

Active, not recruiting

Obesity or Overweight

Drug: Placebo Comparator

Drug: RGT001-075